Wang Xi, Cui Xinyue, Wu Chongyang, Tao Ke, Pan Shuyuan, Wei Wenming
Lab of Novel Bacterial Vaccines Research and Development, Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.
Engineering Research Center of Antibodies, Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.
Vaccines (Basel). 2025 Jul 31;13(8):817. doi: 10.3390/vaccines13080817.
BACKGROUND/OBJECTIVES: Chemically or genetically detoxified pertussis toxin (PTx) is a crucial antigen component of the acellular pertussis vaccine. Chemical detoxification using glutaraldehyde generally causes significant structural changes to the toxin. However, how these structural changes in PTx affect its antigenic properties remains unclear. Additionally, there is limited knowledge regarding how many alterations in antigenic properties impact immunogenicity.
To investigate the impact of structural changes on antigenic properties, we developed a sandwich ELISA to quantify the neutralizing epitopes on PTx. Subsequently, we analyzed different PTx toxoid (PTd) preparations with the assay. Additionally, we assessed the immunogenicity of various acellular pertussis vaccine candidates containing these PTd preparations. Finally, the assay was applied to evaluate the consistency of commercial batches of PTx and PTd intermediates.
The assay demonstrated reasonable specificity, accuracy, and precision, and it was sensitive enough to quantify variations in neutralizing epitopes among different PTd samples that shared the same protein concentration. Importantly, we found a positive correlation between the number of neutralizing epitopes in detoxified PTx and its immunogenicity, indicating that the amount of neutralizing epitopes present determines the immunogenicity of glutaraldehyde-inactivated PTx. Moreover, commercial batches of PTx and PTd intermediates exhibited minor variations in neutralizing epitopes.
These findings have significant implications for developing acellular pertussis vaccines as they highlight the importance of preserving the neutralizing epitopes of PTx during detoxification to ensure the vaccine's effectiveness. This assay is also valuable for the quality control of PTd as it more accurately represents the actual antigenic changes of PTx.
背景/目的:化学或基因解毒的百日咳毒素(PTx)是无细胞百日咳疫苗的关键抗原成分。使用戊二醛进行化学解毒通常会导致毒素发生显著的结构变化。然而,PTx的这些结构变化如何影响其抗原特性仍不清楚。此外,关于抗原特性的多少改变会影响免疫原性的知识也很有限。
为了研究结构变化对抗原特性的影响,我们开发了一种夹心ELISA来定量PTx上的中和表位。随后,我们用该检测方法分析了不同的PTx类毒素(PTd)制剂。此外,我们评估了含有这些PTd制剂的各种无细胞百日咳疫苗候选物的免疫原性。最后,该检测方法被用于评估商业批次的PTx和PTd中间体的一致性。
该检测方法显示出合理的特异性、准确性和精密度,并且灵敏度足以定量相同蛋白质浓度的不同PTd样品之间中和表位的差异。重要的是,我们发现解毒后的PTx中中和表位的数量与其免疫原性之间存在正相关,这表明存在的中和表位数量决定了戊二醛灭活的PTx的免疫原性。此外,商业批次的PTx和PTd中间体在中和表位上表现出微小差异。
这些发现对开发无细胞百日咳疫苗具有重要意义,因为它们突出了在解毒过程中保留PTx中和表位以确保疫苗有效性的重要性。该检测方法对PTd的质量控制也很有价值,因为它更准确地反映了PTx的实际抗原变化。